CN101209300A - Crab apple dispersible tablet and preparation - Google Patents
Crab apple dispersible tablet and preparation Download PDFInfo
- Publication number
- CN101209300A CN101209300A CNA200610172587XA CN200610172587A CN101209300A CN 101209300 A CN101209300 A CN 101209300A CN A200610172587X A CNA200610172587X A CN A200610172587XA CN 200610172587 A CN200610172587 A CN 200610172587A CN 101209300 A CN101209300 A CN 101209300A
- Authority
- CN
- China
- Prior art keywords
- parts
- huahong
- active component
- radix
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a huahong dispersible tablet and the preparation process method thereof. The huahong dispersible tablet is composed of active ingredients, thinners and disintegrating agents, wherein, the thinners are calcium hydrophosphate and microcrystalline cellulose preferentially, and the disintegrating agents are cross-linked polyvinyl pyrrolidone preferentially. The invention further discloses the preparation process of the huahong dispersible tablet and improves the preparation process of the active ingredients. The huahong dispersible tablet of the invention does not contain sugar, the disintegration is rapid, the oral administration is convenient, the invention is used for the treatment of chronic pelvic inflammatory disease and other gynecological inflammations, and the invention can meet the requirements of medication of the patients who are difficult to swallow the tablets and capsules and the patients with diabetes and the patients with obesity.
Description
Technical field
This invention relates to a kind of Chinese patent medicine preparation that is used for the treatment of diseases such as women's chronic pelvic inflammatory disease and preparation method thereof, relates in particular to a kind of dispersible tablet.
Background technology
Chronic pelvic inflammatory disease is a kind of commonly encountered disease, comprises the inflammation of endometritis, adnexitis and pelvic peritoneum and periuterine connective tissue.The pathogen that causes pelvic inflammatory disease mainly contains staphylococcus, escherichia coli etc.This disease sickness rate is higher, reports its sickness rate at 30%-60% according to interrelated data, and state of an illness stubbornness, outbreak repeatedly, and obstinate seriously perplexs women's physical and mental health.At present, this sick medicine of a lot of treatments is arranged on the market, mainly contain FUKE QIANJIN PIAN, HUAHONG PIAN, JINJI JIAONANG etc.Wherein the Guangxi premium Pharmaceutical limited company HUAHONG PIAN curative effect of producing is clear and definite, welcome by consumers in general, 2005 in similar medicine the market share occupy second.Identical with the HUAHONG PIAN prescription in the market HUAHONG KELI, HUAHONG JIAONANG in addition, but these three kinds of dosage forms all have its weak point, as the part particular patients ' to HUAHONG PIAN and HUAHONG JIAONANG dysphagia, and the HUAHONG KELI sugar content is bigger, be not suitable for special populations such as diabetics, obese patient and take, or the like.(patent No. ZL 2,004 1 0060184.7) also disclose a kind of oral liquid formulation that comprises the HUAHONG PIAN active component to patent " Chinese drugs agentia of treatment women's chronic pelvic inflammatory disease and preparation method thereof ", but this dosage form also has the defective of the inconvenience of carrying.Because tablet formulation be able to remedy above-mentioned deficiency, therefore, how HUAHONG PIAN medical material effective ingredient and tablet formulation easy disintegrating, the characteristics of easily taking are effectively combined, prepare Huahong dispersing tablet, to address the above problem, be an important topic of this area research.
Summary of the invention
One of technical issues that need to address of the present invention are to disclose a kind of Huahong dispersing tablet, to overcome the deficiency of existing dosage form, satisfy the treatment needs of above-mentioned particular patients ';
Two of the technical issues that need to address of the present invention are the preparation methoies that disclose described Huahong dispersing tablet, so that suitability for industrialized production.
For addressing the above problem, technical scheme of the present invention is as follows:
Huahong dispersing tablet of the present invention is by active component, diluent and disintegrating agent, and their ratios by weight are:
Active component: 100～300 parts; Diluent: 30～300 parts; Disintegrating agent: 12～60 parts.
Said active component is the feedstock production that adopts following parts by weight:
13～23 parts of 5～15 parts of Radix Urenae Lobataes of 13～23 parts of Herba Hedyotidis Diffusaes of Herba Duchesneae Indicae
10～20 parts of 5～15 portions of Caulis Spatholobis of Radix Malloti Apelitae 5～15 Fen Herba Thlaspiss
13 ~ 23 parts of Radix Rhodomyrtis.
Said active component is to adopt following method preparation:
With Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti is the seven flavor medicine material altogether, decoct with water twice, each amount of water is 6～20 times of medical material gross weight, decocting time is 1～5 hour, filter, it is 1.18～1.23 (80 ℃) that filtrate is concentrated into relative density, gets clear paste A, adding ethanol to alcoholic acid volume content in clear paste A is 50～75%, stir evenly, left standstill 12～36 hours, filter, it is 1.25～1.30 (80 ℃) that filtrate concentrates relative density, get clear paste B, add the silicon dioxide mixing, drying, be ground into fine powder, this fine powder is active component.
Said diluent is one or more in calcium hydrogen phosphate, calcium sulfate, microcrystalline Cellulose, the mannitol;
Said disintegrating agent is one or more in microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linked carboxymethyl cellulose sodium, the carboxymethyl starch sodium;
Through test,
Diluent preferably microcrystalline cellulose and calcium hydrogen phosphate, the weight portion ratio of the two is:
Microcrystalline Cellulose: calcium hydrogen phosphate=10: 12
The preferred crospolyvinylpyrrolidone of disintegrating agent;
The weight portion ratio of active component, diluent and disintegrating agent is preferably:
Active component: 100 parts; 50 parts of microcrystalline Cellulose; Calcium hydrogen phosphate: 60 parts; Crospolyvinylpyrrolidone: 25 parts;
The preparation method of Huahong dispersing tablet of the present invention comprises the steps:
With Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti is the seven flavor medicine material altogether, decoct with water twice, each amount of water is 6～20 times of medical material gross weight, decocting time is 1 ~ 5 hour, filter, it is 1.18～1.23 (80 ℃) that filtrate is concentrated into relative density, gets clear paste A, adding ethanol to alcoholic acid volume content in clear paste A is 50 ~ 75%, stir evenly, left standstill 12～36 hours, filter, it is 1.25～1.30 (80 ℃) that filtrate concentrates relative density, get clear paste B, add the silicon dioxide mixing, drying, be ground into fine powder, get active component.With active component and diluent, part disintegrating agent mixing, wet granulation, 60～80 ℃ of dryings add residue disintegrating agent mixing, and tabletting (ratio by 10000 of per 93.5 kilograms of medical materials compactings is suppressed) promptly obtains Huahong dispersing tablet of the present invention.
Find under study for action, if, lump after the easy moisture absorption of the active component of making directly with clear paste B drying and granulating, and the dry difficulty of doing, storage requirement is had relatively high expectations.After deliberation, be easy to drying after finding in clear paste B, to add a certain amount of silicon dioxide mixing, and can improve the defective of luming after the easy moisture absorption of active component.But silicon dioxide is water insoluble, and dosage too much can influence the mouthfeel of dispersible tablet.Draw through test of many times, be 1～4 part with the weight portion ratio of silicon dioxide and clear paste: 20 parts is proper.
The research of the addition of silicon dioxide
| Silicon dioxide addition (g) | Clear paste amount (g) | Whether be beneficial to drying | Whether lump | The dispersible tablet mouthfeel |
| 1 | ?100 | Not | Be | Very |
| 2 | ?100 | Not | Be | Very |
| 4 | ?100 | Difficult | A little caking | Very |
| 5 | ?100 | Be | Not | Very |
| 10 | ?100 | Be | Not | Very |
| 15 | ?100 | Be | Not | Very |
| 20 | ?100 | Be | Not | Very |
| 25 | ?100 | Be | Not | Difference |
| 30 | ?100 | Be | Not | Difference |
| 40 | ?100 | Be | Not | Difference |
In order to filter out only diluent and disintegrating agent, we have carried out great deal of experimental, below be the part test data: with the disintegration be the examination index (dispersible tablet disintegration: in 20 ℃ ± 1 ℃ water, all disintegrates and sieve in 3 minutes by No. 2.)
| Ratio by weight | Active component | Disintegrating agent | Diluent | Disintegration |
| Prescription one | Active component (100 parts) | Microcrystalline Cellulose (3 parts) | Calcium hydrogen phosphate (50 parts) | 6 minutes |
| Prescription two | Active component (100 parts) | Microcrystalline Cellulose (15 parts)+crospolyvinylpyrrolidone (15 parts) | Microcrystalline Cellulose (30 parts)+calcium hydrogen phosphate (12 parts) | 1 minute 50 seconds |
| Prescription three | Active component (100 parts) | Low-substituted hydroxypropyl cellulose (26 parts) | Mannitol (30 parts) | 1 minute 30 seconds |
| Prescription four | Active component (100 parts) | Cross-linked carboxymethyl cellulose sodium (10 parts) | Calcium sulfate (50 parts) | 4 minutes |
| Prescription five | Active component (100 parts) | Microcrystalline Cellulose (20 parts) carboxymethyl starch sodium (10) | Calcium hydrogen phosphate (50 parts) | 3 minutes 50 seconds |
| Prescription six | Active component (100 parts) | Carboxymethyl starch sodium (30 parts) | Calcium sulfate (50 parts)+calcium hydrogen phosphate (50 parts) | 2 minutes 50 seconds |
| Prescription seven | Active component (100 parts) | Microcrystalline Cellulose (15 parts)+crospolyvinylpyrrolidone (15 parts) | Microcrystalline Cellulose (30 parts)+mannitol (30 parts) | 1 minute 12 seconds |
| Prescription eight | Active component (100 parts) | Crospolyvinylpyrrolidone (25 parts) | Microcrystalline Cellulose (50 parts)+calcium hydrogen phosphate (60 parts) | 1 minute 5 seconds |
From test data as can be seen, select the disintegrating agent of prescription eight and diluent to form collocation for best.
Huahong dispersing tablet of the present invention can be used for treating diseases such as women's chronic pelvic inflammatory disease.Compare with existing HUAHONG PIAN, HUAHONG KELI, HUAHONG JIAONANG, it is rapid that Huahong dispersing tablet of the present invention has a disintegrate, easy-to-swallow, do not contain characteristics such as sugar, so be particularly suitable for crowd, and the patient and the obese patient that are suitable for suffering from diabetes take to dosage form dysphagias such as tablet and capsules.
Huahong dispersing tablet of the present invention can be swallowed routinely, also can insert and treat in the water to take after the disintegrate in several minutes, and dose is 3 slices/time, and 3 times/day, seven days one courses of treatment.
With commercially available HUAHONG JIAONANG is contrast, the animal pharmacological test result who makes of the Huahong dispersing tablet of embodiment one following (two groups of dosage that adopted are converted to effective ingredient and equate):
One, Huahong dispersing tablet of the present invention is to the protective effect of the infection of golden Portugal bacterium, escherichia coli mice
Table 1 Huahong dispersing tablet of the present invention is to the protective effect of golden Portugal bacterium infecting mouse
Compare with the HUAHONG JIAONANG group:
#P＞0.05
Table 2 Huahong dispersing tablet of the present invention is to the protective effect of coli-infection mice
Compare with the HUAHONG JIAONANG group:
#P＞0.05
The result shows: behind the blank group mouse infection staphylococcus aureus 6 hours, 22 hours, 48 hours mortality rates and in 48 hours general mortality rate be respectively 30%, 60%, 10% and 100%, the Huahong dispersing tablet group is respectively 15%, 55%, 10% and 80%, mortality rate after pointing out the Huahong dispersing tablet group to the mouse infection staphylococcus aureus has the trend of protective effect, sees Table 1; Behind the blank group mouse infection escherichia coli 6 hours, 22 hours, 48 hours mortality rates and in 48 hours general mortality rate be respectively 20%, 70%, 5% and 95%; the Huahong dispersing tablet group then is respectively 15%, 55%, 15% and 85%, and the mortality rate of prompting Huahong dispersing tablet group after to the mouse infection escherichia coli also has the trend of protective effect.With the HUAHONG JIAONANG group relatively, the Huahong dispersing tablet group is suitable with the HUAHONG JIAONANG group to the mice protective effect of infecting behind staphylococcus aureus and the escherichia coli.
Two, the analgesic activity of Huahong dispersing tablet of the present invention:
The analgesic activity of table 3 Huahong dispersing tablet of the present invention (writhing method, laboratory animal: mice)
Compare with the blank group: * P＜0.05, compare with the HUAHONG JIAONANG group:
#P＞0.05
The result shows: the Huahong dispersing tablet group has analgesic activity, and to compare effect suitable with the HUAHONG JIAONANG group, sees Table 3.
Three, Huahong dispersing tablet of the present invention is to the influence of fever in rabbits due to the escherichia coli endotoxin
Table 4 Huahong dispersing tablet of the present invention is to the influence of fever in rabbits due to the escherichia coli endotoxin
Compare with the blank group: * P＜0.05, compare with the HUAHONG JIAONANG group:
#P＞0.05
#
The result shows: the fervescence that the Huahong dispersing tablet group causes escherichia coli endotoxin has the effect of obvious suppression, and to compare effect suitable with the HUAHONG JIAONANG group, sees Table 4.
Four, the antiinflammatory action of Huahong dispersing tablet of the present invention
Table 5 Huahong dispersing tablet of the present invention causes the influence of mice auricle swelling to Oleum Tiglii
Compare with the blank group: * P＜0.05, compare with the HUAHONG JIAONANG group:
#P＞0.05
Table 6 Huahong dispersing tablet of the present invention is to the influence of mice granuloma induced by implantation of cotton pellets
Compare with the blank group: * P＜0.05, compare with the HUAHONG JIAONANG group:
#P＞0.05
The result shows: the Huahong dispersing tablet group all has the obvious suppression effect to acute inflammation (Fructus Crotonis oiliness inflammation) and chronic inflammatory disease (granuloma induced by implantation of cotton pellets), and to compare effect suitable with the HUAHONG JIAONANG group, sees Table 5, table 6.
Five, Huahong dispersing tablet of the present invention is to the effect of mice toes blood stasis edema
Table 7 Huahong dispersing tablet of the present invention is to the influence of mice toes blood stasis edema
Compare with the blank group: * P＜0.05, compare with the HUAHONG JIAONANG group:
#P＞0.05
The result shows that the Huahong dispersing tablet group has the obvious suppression effect to mice toes blood stasis edema, compares effect with the HUAHONG JIAONANG group and quite sees Table 7.
The specific embodiment
Embodiment 1
The crude drug prescription:
Herba Duchesneae Indicae 2500 grams, Herba Hedyotidis Diffusae 1500 grams, Radix Urenae Lobatae 2500 grams, Radix Malloti Apelitae 1500 gram ， Herba Thlaspiss 1500 grams, Caulis Spatholobi 2000 grams, Radix Rhodomyrti 2500 grams.
The preparation method of active component:
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 6 times of medical material gross weight, decocting time is 2.5 hours, filter, it is 1.20 (80 ℃) that filtrate decompression is concentrated into relative density, obtains clear paste, and adding ethanol to alcoholic acid content is 60%, stir evenly, left standstill 24 hours, and filtered, filtrate is concentrated into the clear paste (630g) that relative density is 1.25 (80 ℃), add silicon dioxide 32g mixing, 65 ℃ of vacuum dryings are ground into fine powder, obtain active component 300 grams.
Active component and calcium hydrogen phosphate 180 grams, microcrystalline Cellulose 150 grams, polyvinylpolypyrrolidone 35 are restrained mix homogeneously, and wet granulation adds polyvinylpolypyrrolidone 40 gram mixings again, and tabletting promptly gets Huahong dispersing tablet of the present invention.
Embodiment 2
The crude drug prescription:
Herba Duchesneae Indicae 2600 grams, Herba Hedyotidis Diffusae 1000 grams, Radix Urenae Lobatae 2600 grams, Radix Malloti Apelitae 1000 gram ， Herba Thlaspiss 1000 grams, Caulis Spatholobi 2000 grams, Radix Rhodomyrti 2600 grams.
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 8 times of medical material gross weight, decocting time is 2 hours, filter, it is 1.18 (80 ℃) that filtrate decompression is concentrated into relative density, obtains clear paste, and adding ethanol to alcoholic acid content is 50%, stir evenly, left standstill 12 hours, and filtered, filtrate is concentrated into the clear paste (500g) that relative density is 1.25 (80 ℃), add silicon dioxide 80g mixing, 70 ℃ of vacuum dryings are ground into fine powder, obtain active component 320g.
Active component and mannitol 84 grams, low-substituted hydroxypropyl cellulose 53 are restrained mix homogeneously, and wet granulation adds and replaces hydroxypropyl level cellulose 20 gram mixings, and tabletting promptly gets Huahong dispersing tablet of the present invention.
Embodiment 3
The crude drug prescription:
Herba Duchesneae Indicae 2300 grams, Herba Hedyotidis Diffusae 1500 grams, Radix Urenae Lobatae 2300 grams, Radix Malloti Apelitae 1500 gram ， Herba Thlaspiss 1500 grams, Caulis Spatholobi 2000 grams, Radix Rhodomyrti 2300 grams.
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 10 times of medical material gross weight, decocting time is 5 hours, filter, it is 1.23 (80 ℃) that filtrate is concentrated into relative density, obtains clear paste, and adding ethanol to alcoholic acid content is 75%, stir evenly, left standstill 36 hours, and filtered, filtrate is concentrated into the clear paste (600g) that relative density is 1.30 (80 ℃), add silicon dioxide 40g mixing, 80 ℃ of vacuum dryings are ground into fine powder, obtain active component 350g.
Active component and calcium hydrogen phosphate 175 grams, microcrystalline Cellulose 70 grams, crosslinked carboxymethyl fecula sodium 15 are restrained mix homogeneously, and wet granulation adds crosslinked carboxymethyl fecula sodium 20 gram mixings again, and tabletting promptly gets Huahong dispersing tablet of the present invention.
Embodiment 4
The crude drug prescription:
Herba Duchesneae Indicae 1800 grams, Herba Hedyotidis Diffusae 1200 grams, Radix Urenae Lobatae 2000 grams, Radix Malloti Apelitae 1000 gram ， Herba Thlaspiss 1000 grams, Caulis Spatholobi 1500 grams, Radix Rhodomyrti 1800 grams.
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 9 times of medical material gross weight, decocting time is 4 hours, filter, it is 1.20 (80 ℃) that filtrate is concentrated into relative density, obtains clear paste, and adding ethanol to alcoholic acid content is 65%, stir evenly, left standstill 24 hours, and filtered, filtrate decompression is concentrated into the clear paste (460g) that relative density is 1.30 (80 ℃), add silicon dioxide 50g mixing, 65 ℃ of vacuum dryings are ground into fine powder, obtain active component 280 grams.
Active component and calcium hydrogen phosphate 140 grams, cross-linked carboxymethyl cellulose sodium 14 are restrained mix homogeneously, and wet granulation adds cross-linked carboxymethyl cellulose sodium 14 gram mixings again, and tabletting promptly gets Huahong dispersing tablet of the present invention.
Embodiment 5
The crude drug prescription:
Herba Duchesneae Indicae 1500 grams, Herba Hedyotidis Diffusae 1500 grams, Radix Urenae Lobatae 1800 grams, Radix Malloti Apelitae 1200 gram ， Herba Thlaspiss 1000 grams, Caulis Spatholobi 1500 grams, Radix Rhodomyrti 2000 grams.
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 8 times of medical material gross weight, decocting time is 1 hour, filter, it is 1.20 (80 ℃) that filtrate is concentrated into relative density, obtains clear paste, and adding ethanol to alcoholic acid content is 60%, stir evenly, left standstill 24 hours, and filtered, filtrate decompression is concentrated into the clear paste (485g) that relative density is 1.30 (80 ℃), add silicon dioxide 50g mixing, 65 ℃ of vacuum dryings are ground into fine powder, obtain active component 290 grams.
Active component and mannitol 87 grams, microcrystalline Cellulose 130 grams, crospolyvinylpyrrolidone 44 are restrained mix homogeneously, and wet granulation adds crospolyvinylpyrrolidone 24 grams again, mixing, and tabletting promptly gets Huahong dispersing tablet of the present invention.
Claims (7)
1. a Huahong dispersing tablet is characterized in that, it comprises active component, diluent and disintegrating agent, and three's parts by weight ratio is:
Active component: 100～300 parts; Diluent: 30～300 parts; Disintegrating agent: 12～60 parts.
Said active component is the feedstock production that adopts following parts by weight:
13～23 parts of 5～15 parts of Radix Urenae Lobataes of 13～23 parts of Herba Hedyotidis Diffusaes of Herba Duchesneae Indicae
10～20 parts of 5～15 portions of Caulis Spatholobis of Radix Malloti Apelitae 5～15 Fen Herba Thlaspiss
13～23 parts of Radix Rhodomyrtis
Said diluent is one or more in calcium hydrogen phosphate, calcium sulfate, microcrystalline Cellulose, the mannitol;
Said disintegrating agent is one or more in microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linked carboxymethyl cellulose sodium, the carboxymethyl starch sodium.
2. Huahong dispersing tablet according to claim 1 is characterized in that, the weight portion ratio of described active component, diluent and disintegrating agent is:
Active component: 100 parts; Diluent: 110 parts; Disintegrating agent: 25 parts.
3. Huahong dispersing tablet according to claim 2 is characterized in that, described diluent is microcrystalline Cellulose and calcium hydrogen phosphate, and disintegrating agent is a crospolyvinylpyrrolidone.
4. Huahong dispersing tablet according to claim 3 is characterized in that, the weight portion ratio of described active component, diluent and disintegrating agent is:
Active component: 100 parts; 50 parts of microcrystalline Cellulose; Calcium hydrogen phosphate: 60 parts; Crospolyvinylpyrrolidone: 25 parts.
5. according to the described Huahong dispersing tablet of claim 1～4, it is characterized in that the preparation of described active component may further comprise the steps:
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 6～20 times of medical material gross weight, each decocting time is 1～5 hour, filter, filtrate merges, concentrating under reduced pressure, obtain clear paste, adding ethanol to alcoholic acid volume content is 50～75%, stirs evenly, and leaves standstill, filter, filtrate is concentrated into the clear paste B that relative density is 1.25～1.30 (80 ℃), adds the silicon dioxide mixing, drying, pulverize, obtain active component.
6. the preparation method of active component according to claim 5 is characterized in that, the weight portion ratio of described silicon dioxide and described clear paste B is:
Silicon dioxide: 1～4 part; Clear paste B:20 part.
7. according to the described Huahong dispersing tablet of claim 1-4, it is characterized in that its preparation method may further comprise the steps:
Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Caulis Spatholobi, Radix Rhodomyrti are total to the seven flavor medicine material, decoct with water twice, each amount of water is 6～20 times of medical material gross weight, each decocting time is 1～5 hour, filter, filtrate merges, concentrating under reduced pressure, obtain clear paste, adding ethanol to alcoholic acid volume content is 50～75%, stirs evenly, and leaves standstill, filter, filtrate is concentrated into the clear paste that relative density is 1.25～1.30 (80 ℃), adds the silicon dioxide mixing, drying, pulverize, obtain active component.Then in proportion with active component and diluent, part disintegrating agent mixing, wet granulation, 60～80 ℃ of dryings add residue disintegrating agent mixing, tabletting, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610172587XA CN101209300A (en) | 2006-12-27 | 2006-12-27 | Crab apple dispersible tablet and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610172587XA CN101209300A (en) | 2006-12-27 | 2006-12-27 | Crab apple dispersible tablet and preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101209300A true CN101209300A (en) | 2008-07-02 |
Family
ID=39609664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200610172587XA Pending CN101209300A (en) | 2006-12-27 | 2006-12-27 | Crab apple dispersible tablet and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101209300A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585322A (en) * | 2012-08-14 | 2014-02-19 | 广西壮族自治区花红药业股份有限公司 | Novel preparation technology of Huahong tablet |
-
2006
- 2006-12-27 CN CNA200610172587XA patent/CN101209300A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585322A (en) * | 2012-08-14 | 2014-02-19 | 广西壮族自治区花红药业股份有限公司 | Novel preparation technology of Huahong tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN101683420B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating acute pharyngitis | |
| CN101564458A (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN101057892B (en) | Medicinal composition for treating vaginal diseases and its preparation method and application | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN101732467B (en) | Application of Chinese medicinal composition in preparation of medicament for treating purulent pleurisy | |
| CN101658585B (en) | Application of Chinese medicinal composition in preparing medicament for treating nasosinusitis | |
| CN101683422B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating cough variant asthma | |
| CN101912376B (en) | Matrine vaginal effervescent tablets with bilayer structure and preparation method | |
| CN101209300A (en) | Crab apple dispersible tablet and preparation | |
| CN1899392B (en) | Chinese medicine composition for treating gynecological inflammation and its preparing method and use | |
| CN100518720C (en) | Orally quick-acting tablet of ginseng stem leaf saponin including orally disintegrating tablet and dispersible tablet and method for preparing the same | |
| CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101632777A (en) | Chinese medicinal composition for clearing away heat and toxic material, dispersing food and freeing bowels and preparation method thereof | |
| CN1931279A (en) | Medicine for treating biliary tract infection and its prepn process | |
| CN1943662B (en) | Preparation method of the Chinese traditional medicinal composition granules for treating galactophore disease and its products | |
| CN1954841B (en) | Medicine for treating chronic pharyngitis | |
| CN104474275A (en) | Preparation method of traditional Chinese medicine composition for treating acute and chronic pharyngitis and preparation thereof | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080702 |